Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 676 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Morning Group Clear all
Completed Phase 3 Interventional Results available

GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

NCT00712673
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Lixisenatide (AVE0010), Placebo, Pen auto-injector, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 22, 2026, 2:00 AM EDT
Completed Not applicable Interventional Results available

A Pharmacist Intervention for Monitoring and Treating Hypertension Using Bidirectional Texting

NCT03986931
View directory record Official record
Conditions
Hypertension
Interventions
Experimental: Pharmacist-Bidirectional Texting Group, Active Comparator: Control Group
Other
Lead sponsor
Linnea Polgreen
Other
Eligibility
21 Years to 100 Years
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Oct 22, 2026, 2:00 AM EDT
Completed Phase 3 Interventional Results available

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

NCT00464269
View directory record Official record
Conditions
Epilepsy
Interventions
Placebo, Brivaracetam 2.5 mg, Brivaracetam 10 mg, Brivaracetam 25 mg
Other · Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 22, 2026, 2:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

At-Home Diaphragmatic Interventions for Voiding Abnormalities (DIVA)

NCT06165731
View directory record Official record
Conditions
Dysfunctional Voiding, Urinary Dysfunction
Interventions
Diaphragmatic Breathing Exercises, Bladder Hygiene Education
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 22, 2026, 2:00 AM EDT
Recruiting Phase 1 Interventional

Impact of Sodium Bicarbonate on 24-hour Urine Parameters in Hypocitriuric and Uric Acid Stone Formers

NCT06335537
View directory record Official record
Conditions
Uric Acid Stones
Interventions
Potassium citrate, Sodium bicarbonate
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Oct 22, 2026, 2:00 AM EDT
Completed Phase 3 Interventional Results available

Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus Trisulfate Solution Using 2-Day Split-Dosing Regimen in Adults

NCT02254486
View directory record Official record
Conditions
Colon Cancer, Colorectal Carcinoma, Colon Cleansing
Interventions
NER1006, Trisulfate solution
Drug
Lead sponsor
Norgine
Industry
Eligibility
18 Years to 85 Years
Enrollment
621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
Anaheim, California • Annapolis, Maryland • Chevy Chase, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 22, 2026, 2:00 AM EDT
Completed Phase 3 Interventional Results available

Individualized Obesity Pharmacotherapy

NCT03374956
View directory record Official record
Conditions
Obesity
Interventions
Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion, Phentermine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 22, 2026, 2:00 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS)

NCT05469464
View directory record Official record
Conditions
Atopic Dermatitis, Skin Diseases
Interventions
Orismilast modified release tablets, Placebo
Drug
Lead sponsor
UNION therapeutics
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
18
States / cities
Canoga Park, California • Fountain Valley, California • Inglewood, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 22, 2026, 2:00 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00735371
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
LDX 30 mg, LDX 50 mg, LDX 70 mg, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
13 Years to 17 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
45
States / cities
Little Rock, Arkansas • El Centro, California • Rolling Hills Estates, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 22, 2026, 2:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of a Female Hormone Balance Supplement on Symptoms of Polycystic Ovary Syndrome and Severe Premenstrual Syndrome

NCT06124300
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Premenstrual Syndrome
Interventions
Female Hormone Balance Supplement
Dietary Supplement
Lead sponsor
Rael
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 22, 2026, 2:00 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients

NCT01798706
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Lixisenatide (AVE0010), Placebo, Antidiabetic background therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
70 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
14
States / cities
La Jolla, California • Norwalk, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 22, 2026, 2:00 AM EDT
Recruiting No phase listed Observational

Application of a Clinical Decision Support System to Reduce Mechanical Ventilation Duration After Cardiac Surgery in Children

NCT05687292
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Clinical decision support system (CDSS) for ventilator weaning
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Day to 12 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 22, 2026, 2:00 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaban

NCT02207257
View directory record Official record
Conditions
Anticoagulation Reversal
Interventions
PER977, Placebo, Edoxaban
Drug
Lead sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 22, 2026, 2:00 AM EDT
Withdrawn Phase 4 Interventional

A Pilot Study Investigating the Efficacy of Minocycline and N-Acetyl Cysteine for Bipolar Depression

NCT02719392
View directory record Official record
Conditions
Bipolar Disorder, Bipolar Depression
Interventions
N-acetylcysteine, Minocycline, Placebo
Dietary Supplement · Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 22, 2026, 2:00 AM EDT
Recruiting Phase 3 Interventional

Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes

NCT07216235
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Saroglitazar magnesium 1 mg, Placebo
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
3
States / cities
Marietta, Georgia • Indianapolis, Indiana • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 22, 2026, 2:00 AM EDT
Terminated Not applicable Interventional Results available

Efficacy of Lubiprostone in Combination With Standard PEG Preparation

NCT00689026
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Lubiprostone, Polyethylene glycol with electrolytes
Drug · Other
Lead sponsor
Augusta University
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 20, 2014 · Synced Oct 22, 2026, 2:00 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention

NCT02848326
View directory record Official record
Conditions
Migraine, With or Without Aura
Interventions
Atogepant, Placebo-matching Atogepant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
834 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
75
States / cities
Birmingham, Alabama • Chandler, Arizona • Carlsbad, California + 66 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Oct 22, 2026, 2:00 AM EDT
Completed Not applicable Interventional

Randomized Trial of a Gum Health Formulation

NCT03196648
View directory record Official record
Conditions
Periodontal Diseases, Gingivitis, Periodontitis, Halitosis
Interventions
Gingival health formulation in an accelerating device, Gingival health formulation on a toothbrush, OTC fluoride toothpaste
Other
Lead sponsor
Glo Science, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 22, 2026, 2:00 AM EDT
Terminated Phase 4 Interventional Results available

Mindfulness Based Smoking Cessation Among Cancer Survivors

NCT04038255
View directory record Official record
Conditions
Tobacco Smoking
Interventions
Nicoderm C-Q Transdermal Product, Orientation session, Craving-to-Quit app, Two brief follow-up phone calls, Group MT sessions, Brief advice on quitting smoking, Self-help smoking cessation materials
Drug · Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Miami, Florida • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 22, 2026, 2:00 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Role of Metformin on Muscle Health of Older Adults

NCT03107884
View directory record Official record
Conditions
Muscle Atrophy, Insulin Resistance
Interventions
Metformin (Bed Rest), Placebo (Bed Rest), Metformin (2 week run-in only), Placebo (2 week run-in only)
Drug
Lead sponsor
University of Utah
Other
Eligibility
60 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 22, 2026, 2:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunteers and in Patients With Dry Eye

NCT01319773
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
cyclosporine ophthalmic emulsion Formulation A, cyclosporine ophthalmic emulsion Formulation B, cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion 0.05%, cyclosporine ophthalmic emulsion Formulation B; cyclosporine ophthalmic emulsion 0.05%, cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion Formulation B
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2015 · Synced Oct 22, 2026, 2:00 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults

NCT07392723
View directory record Official record
Conditions
Cognitive Dysfunction, Alzheimer Disease, Blood-Brain Barrier, Apolipoprotein E, Deficiency or Defect of, Brain Aging, Fatty Acids, Omega-3
Interventions
Alpha-Linolenic Acid (2.6 g/day), Placebo Control Group
Drug · Dietary Supplement
Lead sponsor
Michal Schnaider Beeri, Ph.D.
Other
Eligibility
60 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 22, 2026, 2:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Heart Health 4 New Moms: A Randomized Trial in the First Year After Preeclampsia

NCT03749746
View directory record Official record
Conditions
Preeclampsia, Gestational Hypertension, Hypertension, Obesity, Overweight and Obesity, Pregnancy Complications, Pregnancy Toxemia, Postpartum Preeclampsia
Interventions
Home Blood Pressure Monitoring, Heart Health 4 New Moms, Usual care
Behavioral · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 22, 2026, 2:00 AM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation

NCT03120520
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
Plecanatide, Matching placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
36
States / cities
Foley, Alabama • Jonesboro, Arkansas • Cerritos, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2019 · Synced Oct 22, 2026, 2:00 AM EDT